Nimodipine
Who holds supplier records for Nimodipine? 5 organisations hold a current record for Nimodipine: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 3 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (3), Italy (1) and Spain (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Nimodipine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/nimodipine
Reading the evidence
- 5 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
3 of the 5 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 2 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Nimodipine expires 16 Apr 2038. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (5)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Nimodipine. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaCEPActive DMF 34203 · latest filing Dec 2019
- LUSOCHIMICA SPAItalyCEP Company GMP cert on recordActive DMF 14979 · latest filing Jul 2000
- UNION QUIMICO FARMACEUTICA SA (UQUIFA SA)SpainCEPActive DMF 16951 · latest filing Nov 2003
- DASAMI LAB PRIVATE LTDIndia Company GMP cert on recordActive DMF 32971 · latest filing Oct 2018
- Laksh Fine Chem Private LimitedIndiaActive DMF 43602 · latest filing Feb 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (3)
Certificates of Suitability on the EDQM register for Nimodipine, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 4 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| LUSOCHIMICA S.P.A. Lomagna | IT | CEP 2022-403 - Rev 00 Nimodipine | Jan 2024 | Inspected Oct 2023 Italy, outside 3-year window |
| Union Quimico Farmaceutica, S.A. (Uquifa S.A.) Barcelona | ES | CEP 2004-272 - Rev 03 Nimodipine | Oct 2023 | — |
| BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. Hyderabad | IN | R0-CEP 2020-353 - Rev 00 Nimodipine | Oct 2022 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (2)
Organisations whose Type II DMFs for Nimodipine are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- India · Inactive DMF 17849 · filed Nov 2004
- BAYER HEALTHCARE AGInactive DMF 4664 · filed Sept 1982
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (6 listed products contain Nimodipine). The latest listed patent expires 16 Apr 2038. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Nimodipine is a calcium channel blocker primarily used to reduce brain damage caused by a lack of oxygen brought on by bleeding from a burst blood vessel. It works by relaxing narrowed blood vessels in the brain, facilitating improved blood flow.
Chemical identity
- IUPAC name
- 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- Canonical SMILES
- CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
- InChIKey
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N
- Synonyms
- Nimotop API, (±)-nimodipine, admon, bay e 9736, bay-e-9736, nemotan, nimodipine ap, nimotop, nsc-758476, nymalize, periplum
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Dihydropyridine Calcium Channel Blocker
- Mechanism of action
- Calcium Channel Antagonists
- Chemical structure
- Dihydropyridines
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Nimodipine?
5 organisations hold an active US FDA Type II Drug Master File or a CEP for Nimodipine: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), LUSOCHIMICA SPA (Italy), UNION QUIMICO FARMACEUTICA SA (UQUIFA SA) (Spain), DASAMI LAB PRIVATE LTD (India) and Laksh Fine Chem Private Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Nimodipine Drug Master Files are active?
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 34203), LUSOCHIMICA SPA (DMF 14979), UNION QUIMICO FARMACEUTICA SA (UQUIFA SA) (DMF 16951), DASAMI LAB PRIVATE LTD (DMF 32971) and Laksh Fine Chem Private Limited (DMF 43602). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Nimodipine records mean?
2 organisations have only inactive Type II DMFs for Nimodipine. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Nimodipine have a European Certificate of Suitability?
Yes. 3 organisations hold a valid CEP for Nimodipine on the EDQM register, including LUSOCHIMICA S.P.A. Lomagna (IT), Union Quimico Farmaceutica, S.A. (Uquifa S.A.) Barcelona (ES) and BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. Hyderabad (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Nimodipine?
Yes. The latest patent listed for an approved US product containing Nimodipine expires 16 Apr 2038, across 6 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Nimodipine supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Nimodipine?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.